A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

Inclusion Criteria: * Subjects and their guardians must sign an informed consent form. The research protocol/informed consent form for data collection and data verification should comply with local laws and regulations. * Age 4 years ≤ age ≤ 17 years, regardless of gender; * Subjects weigh ≥ 15kg; * Subjects who respond poorly to local treatment and/or phototherapy or are unsuitable for such treatments; * Diagnosed with severe plaque psoriasis in children according to the "Chinese Expert Consensus on the Diagnosis and Treatment of Pediatric Psoriasis (2021)" Exclusion Criteria: * Based on the prescribing information of Adalimumab Solution for Injection and the judgment of the treating physician, the subject is not eligible for treatment with Adalimumab Solution for Injection; * Subjects who received psoralen combined with long-wave ultraviolet (UVA) therapy within 14 days prior to the screening period, or topical medium-wave ultraviolet (UVB) therapy within 7 days prior to the screening period; * Subjects who received non-biological systemic treatments for paediatric psoriasis within 14 days prior to the screening period; * Subjects who are currently using or have used other biological Disease-Modifying Antirheumatic Drug treatments within 12 weeks prior to the screening period; * Subjects with significantly active psoriasis within 12 weeks prior to enrolment; * Subjects who have received any live vaccine within 3 months prior to the first dose of Adalimumab Solution for Injection, or who plan to receive live vaccines during the study; * Subjects currently participating in other clinical studies; * Subjects deemed unsuitable for participation in this trial by the investigator.